FGF23 and left ventricular hypertrophy: Although the underline mechanism has not been elucidated, it is suggested that exogenous erythropoietin generated by ESAs can largely increase C-terminal fibroblast growth factor 23 (FGF23) level (25), which is significantly associated with left ventricular hypertrophy and an increased risk of mortality.